Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01596387|
Recruitment Status : Completed
First Posted : May 11, 2012
Last Update Posted : May 11, 2012
The purpose of this study is to validate an integrated pharmacokinetic-pharmacodynamic model to administer propofol in obese patients.
Our hypothesis is that pharmacokinetic and pharmacodynamic changes occur with increasing weight and that mathematical models to administer drugs in obese patients can be developed to accurately predict dose schemes in this population.
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Drug: Propofol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||May 2012|
20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
- Validated pharmacokinetic-pharmacodynamic model of Propofol in Obese patients [ Time Frame: During the intraoperative period and until 120 min after stopping propofol infusion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01596387
|Hospital Clinico Pontificia Universidad Catolica|
|Santiago, Region Metropolitana, Chile|
|Principal Investigator:||Luis I Cortínez, MD||Departamento de Anestesiología, Hospital Clínico Pontificia Universidad Católica de Chile|